At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Placebo gel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind, Randomized, Placebo-controlled Phase 2 Pilot Study to Investigate the Safety and Clinical Outcomes of 1.0 % Topically Applied GLYC-101, Compared to Placebo, in Healthy Subjects Undergoing Retro-auricular Carbon Dioxide Laser Skin Resurfacing.
In Brief
A Phase 2 clinical trial evaluating Placebo gel and GLYC-101 gel (1.0 %) for Wounds. Completed, enrolled 12 participants across 1 site.
Detailed Summary
Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWounds
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
Primary CompletionApr 2008
First PostedApr 2008
Study CompletionAug 2008
TodayJul 2026
First PostedApr 11, 2008
Enrollment StartMar 1, 2008
Primary CompletionApr 1, 2008
Study CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 18.2 years ago
Interventions
Placebo geldrug
Administration of Placebo gel on Day 1, 3 and 5 post ablation.
GLYC-101 gel (1.0 %)drug
Administration on Day 1, 3 and 5 post laser ablation.